The Law Offices of Timothy L. Miles Is Investigating the Officers and Directors of Poseida Therapeutics, Inc. (PSTX) on Behalf of Shareholders
Poseida conducted its IPO on July 10, 2020, issuing 14 million shares for $16.00 per share. On August 18, 2020, Poseida announced that the U.S. Food and Drug Administration had placed a clinical hold on its Phase 1 clinical trial evaluating the autologous CAR-T therapy P-PSMA-101 in patients with metastatic castration-resistant prostate cancer due to a patient’s death. On this news, Poseida’s stock fell 30.31%, to close at $9.06 on August 18, 2020.
If you are a concerned shareholder who owns shares in PSTX and would like more information about your rights and potential remedies you can call us toll-free at 855-846-6529 or send us a message via the Shareholder Information below or by email to firstname.lastname@example.org.